Soleno Therapeutics, Inc. (NASDAQ:SLNO) Director Matthew Pauls Sells 5,937 Shares

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Director Matthew Pauls sold 5,937 shares of the firm’s stock in a transaction that occurred on Friday, March 28th. The shares were sold at an average price of $71.55, for a total transaction of $424,792.35. Following the completion of the transaction, the director now directly owns 6,500 shares of the company’s stock, valued at $465,075. This represents a 47.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Soleno Therapeutics Trading Down 4.5 %

SLNO stock opened at $68.26 on Wednesday. The stock has a market cap of $3.13 billion, a P/E ratio of -20.56 and a beta of -1.70. Soleno Therapeutics, Inc. has a twelve month low of $36.61 and a twelve month high of $73.97. The company’s 50 day moving average is $49.82 and its two-hundred day moving average is $50.34.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41). On average, equities research analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Analyst Ratings Changes

SLNO has been the topic of several analyst reports. Lifesci Capital upgraded Soleno Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 4th. Laidlaw boosted their price objective on Soleno Therapeutics from $75.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, March 27th. Cantor Fitzgerald upped their target price on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. HC Wainwright boosted their price target on shares of Soleno Therapeutics from $70.00 to $100.00 and gave the stock a “buy” rating in a report on Monday. Finally, Robert W. Baird raised their price objective on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, March 27th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $98.86.

Institutional Trading of Soleno Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SLNO. AlphaQuest LLC increased its position in Soleno Therapeutics by 1,154.4% during the fourth quarter. AlphaQuest LLC now owns 715 shares of the company’s stock worth $32,000 after buying an additional 658 shares during the period. US Bancorp DE acquired a new position in shares of Soleno Therapeutics in the 4th quarter valued at $34,000. Avanza Fonder AB purchased a new stake in Soleno Therapeutics in the 4th quarter valued at $76,000. Springhill Fund Asset Management HK Co Ltd acquired a new stake in Soleno Therapeutics during the 4th quarter worth $81,000. Finally, Avior Wealth Management LLC purchased a new position in Soleno Therapeutics during the 4th quarter worth $89,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.